
Novo Doubles Down on Oral Obesity Meds With Septerna Deal Worth up to $2.4B
Novo Nordisk is looking to stay on top of the obesity drug market as competitors race ahead, striking a deal with Septerna to co-develop small molecule oral obesity drugs. Novo is fronting $200 million off the bat and up to $2.2 billion in R&D and …